Determination of Salivary CD44 as a Noninvasive Diagnostic Biomarker to Predict Malignant Transformation of Oral Submucous Fibrosis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cluster of differentiation 44 (CD44) levels in saliva showed a non-significant decrease in oral submucous fibrosis (OSMF) patients and with disease progression. Further research is needed to confirm CD44’s diagnostic potential for OSMF.
Area Of Science
- Oral pathology
- Biomarker discovery
- Cancer stem cell research
Background
- Oral potentially malignant disorders (OPMDs) like oral submucous fibrosis (OSMF), leukoplakia, and oral cancer are associated with cancer stem cells.
- Cluster of differentiation 44 (CD44) is a stem cell marker found in saliva, but its diagnostic value in OSMF is unproven.
Purpose Of The Study
- To investigate CD44 expression in the saliva of OSMF patients.
- To assess the potential of salivary CD44 as a noninvasive diagnostic marker for OSMF.
Main Methods
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify salivary CD44 levels in 30 OSMF patients and 30 controls.
- OSMF grading was based on clinical and histopathological assessments.
- Statistical analyses included Chi-square test, independent t-test, ANOVA, and correlation analyses.
Main Results
- Mean salivary CD44 levels were 5.57 ± 0.77 pg/ml in controls and 5.37 ± 0.76 pg/ml in OSMF patients, a non-significant decrease.
- Salivary CD44 levels showed a trend of decreasing with increasing OSMF grades.
Conclusions
- Salivary CD44 expression may decrease with OSMF progression and severity.
- Larger sample sizes are required to validate CD44 as a reliable molecular biomarker for OSMF diagnosis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.